Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Maravai Lifesciences Holdings (MRVI) and Sarepta Therapeutics (SRPT)

Tipranks - Tipranks - Fri Feb 27, 4:52AM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Veracyte (VCYT – Research Report), Maravai Lifesciences Holdings (MRVI – Research Report) and Sarepta Therapeutics (SRPT – Research Report).

Claim 50% Off TipRanks Premium

Veracyte (VCYT)

In a report released today, Andrew Brackmann from William Blair reiterated a Buy rating on Veracyte. The company’s shares closed last Wednesday at $35.72.

According to TipRanks.com, Brackmann is a 4-star analyst with an average return of 16.1% and a 59.5% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

Currently, the analyst consensus on Veracyte is a Moderate Buy with an average price target of $46.25, which is a 29.3% upside from current levels. In a report released today, TipRanks – DeepSeek also upgraded the stock to Buy with a $40.00 price target.

See the top stocks recommended by analysts >>

Maravai Lifesciences Holdings (MRVI)

Guggenheim analyst Subbu Nambi maintained a Hold rating on Maravai Lifesciences Holdings yesterday. The company’s shares closed last Wednesday at $3.26, close to its 52-week low of $2.07.

According to TipRanks.com, Nambi is a 5-star analyst with an average return of 24.7% and a 56.8% success rate. Nambi covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Adaptive Biotechnologies, and Nautilus Biotechnolgy. ;'>

Currently, the analyst consensus on Maravai Lifesciences Holdings is a Moderate Buy with an average price target of $4.50, a 42.9% upside from current levels. In a report released today, William Blair also maintained a Hold rating on the stock.

Sarepta Therapeutics (SRPT)

In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics, with a price target of $26.00. The company’s shares closed last Wednesday at $18.97.

According to TipRanks.com, Ear is a 1-star analyst with an average return of -0.5% and a 36.7% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and Cartesian Therapeutics. ;'>

Sarepta Therapeutics has an analyst consensus of Hold, with a price target consensus of $22.27.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).